Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
The study will start with a run-in period with controlled diet and no drug for 5 consecutive
days. This is to accustom the subjects to the standardized diet and also to determine
baseline fecal fat excretion.
After run-in period, subjects will be randomized to receive either test or reference orlistat
formulations (60 mg or 120 mg) thrice daily under fed conditions for 10 consecutive days.